Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
  • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
  • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

• the compounds are 11-aminoalkylidenemorphanthridines which are useful as central nervous system depressants, skeletal muscle relaxants and antitremor agents.
• Representative of the compounds disclosed are 11- (3 dimethylaminopropylidene)morphanthridine and 2- chloro-l 1 (3-dimethylaminopropylidene)morphanthridine.
• R and R are selected from hydrogen, lower alkyl of 1 to 4 carbon atoms such as methyl, ethyl or isopropyl, a phenyl-lower alkyl of 7 to 13 carbon atoms such as benzyl, phenethyl or phenylisopropyl, a cycloalkyl of 3 to 7 carbon atoms such as cyclopropyl, cyclopentyl and cyclohexyl and cycloalkyl-lower alkyl groups in which the cycloalkyl group contains 3 to 7 carbon atoms such as cyclopentyl-ethyl and cyclohexylmethyl or (b) a heterocyclic amino group such as morpholino, pyrrolidino, piperidino, N-lower alkyl piperazino such as N-methylpiperazino, N-phenyl-lower alkyl piperazino groups such as N-benzyl piperazino and
• the compounds of the present invention may be conveniently prepared from the corresponding substituted 11- morphanthridones which have the following formula:
• the compounds are prepared by the reaction of the ll-morphanthridone and an aminoalkylphosphonium compound and a strong base such as butyl lithium.
• the reaction is preferably carried out in a mutual solvent, such as tetrahydrofuran, at reflux.
• the reaction is generally complete in about 10 hours and the desired morphanthridine derivative isolated by conventional techniques.
• EQJHRKCHQ nAm in which R is an alkyl group of 1 to 4 carbon atoms, phenyl, aminophenyl or benzyl, and R n and Am are as defined previously.
• aminoalkylphosphonium compounds may be prepared as described in U.S. Pat. No. 3,354,155. Representative of such compounds which may be employed are the following:
• the compounds of the present invention have been found to possess utility as pharmaceutical agents, especially central nervous system depressants and agents for treating Parkinsons disease and drug induced extra pyramidal disorders.
• central nervous system depressants especially central nervous system depressants and agents for treating Parkinsons disease and drug induced extra pyramidal disorders.
• the compounds ll-(3-dimethylaminopropylidene)morphanthridine and 2-chloro-11-(3-dimethylaminopropylidene)morphanthridine were found in doses of 10 mg./kg. intraperitoneally to cause centralnervous system depression.
• the studies also indicated .that the compounds had LD s in excess of 150 mg./ kg. intraperitoneally.
• Each of the forementioned compounds were also tested for antitremor activity.
• the compounds were administered to mice in doses of 0.3 to 30 mg./kg. intraperitoneally prior to challenge with oxotremorine.
• x0- tremorine when administered to normal nonmedicated animals produces a tremor, rigidity, and parasympathomimetic stimulation which very closely resembles the rigidity and tremor of Parkinsons disease.
• the compounds When employed as pharmaceutical agents the compounds are preferably used in the form of acid addition salts.
• acid addition salts may be conveniently prepared by conventional means such as by contacting the compounds with a suitable acid in a mutual solvent and then removing the solvent to obtain the desired salt.
• acids which may be used are hydrochloric acid, succinic acid, tartaric acid, benzoic acid or fu-maric acid.
• Quaternary ammonium salts of the compounds may be formed by conventional techniques employing a suitable alkylating agent such as methyl chloride, methyl iodide or ethyl bromide.
• Pharmaceutical dosage forms containing the active ingredients are generally prepared by combining the active ingredients or ingredients with a major amount of one or more suitable pharmaceutical diluents and then forming the resulting mixture into unit dosage forms suitable for oral or parenteral administration.
• the unit dosage forms will generally contain from 5 to 250 mg. of the active ingredients. One or more of such units may be administered daily depending upon the patients physical size and the severity of the condition being treated. However, generally the daily dosage will not exceed 150 mg. of the active ingredient per kilogram of the patients body weight.
• composition which may be prepared are the following:
• the powders, other than magnesium stearate, are granulated with water, passed through a No. 16 mesh screen and dried at 50 C. Magnesium stearate is mixed in and 40 mg. tablets are pressed.
• Example 3 The process of Example 1 may be repeated using in place of 3 demthylaminopropyltriphenylphosphonium bromide hydrobromide one of the following:
• Example 2 may be "repeated using in place of 3 dimethylaminopropyltriphenylphosphonium bromide hydrobromide one of the following:
• a heterocyclic amino group selected from morpholino, pyrrolidino, piperidino, N lower alkyl piperazino, N phenyl lower alkyl piperazino and N-(hydroxy-lower alkyl)-piperazin0.
• Y is chloro, R is hydrogen and Am is in which R and R are methyl.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Other In-Based Heterocyclic Compounds (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=25303045

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (5)

Family Cites Families (2)

• 1969
  • 1969-08-07 US US848355A patent/US3699099A/en not_active Expired - Lifetime
• 1970
  • 1970-06-22 ZA ZA704266A patent/ZA704266B/xx unknown
  • 1970-07-17 GB GB3482870A patent/GB1304069A/en not_active Expired
  • 1970-07-17 DE DE2035517A patent/DE2035517C3/de not_active Expired
  • 1970-07-20 ES ES381989A patent/ES381989A1/es not_active Expired
  • 1970-07-27 BE BE753958D patent/BE753958A/fr unknown
  • 1970-07-29 FR FR7027913A patent/FR2060085B1/fr not_active Expired
  • 1970-08-06 JP JP45068418A patent/JPS504675B1/ja active Pending

Also Published As

Similar Documents